The Finviz mobile app for iOS and Android. Get the Mobile App
Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year · Ends Dec 30, 19:00 ET

Last Close
0.8000
Nov 10 • 3:59 PM ET Dollar change0.0000 Percentage change(0.00%)
Nov 10, 6:53 PMTELA Bio beats Q3 loss expectations with $0.13 adjusted loss vs $0.19 consensus as cost cuts drive EBITDA improvement amid PRS-driven 8% revenue decline
Index
-
Market Cap
36.11M
Enterprise Value
62.30M
Income
-41.18M
Sales
79.91M
Book/sh
-0.35
Cash/sh
0.67
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
218
IPO
Nov 08, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
0.45
P/B
-
P/C
1.19
P/FCF
-
EV/EBITDA
-
EV/Sales
0.78
Quick Ratio
2.38
Current Ratio
2.99
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.77
EPS next Y
-0.44
EPS next Q
-0.12
EPS this Y
18.33%
EPS next Y
34.54%
EPS next 5Y
26.12%
EPS past 3/5Y
32.78% 17.97%
Sales past 3/5Y
24.68% 34.54%
EPS Y/Y TTM
30.65%
Sales Y/Y TTM
6.09%
EPS Q/Q
10.29%
Sales Q/Q
-4.49%
Insider Own
25.99%
Insider Trans
1.54%
Inst Own
42.52%
Inst Trans
-3.69%
ROA
-64.71%
ROE
-616.62%
ROIC
-102.40%
Gross Margin
67.81%
Oper. Margin
-42.56%
Profit Margin
-51.53%
SMA20
-13.73%
SMA50
-22.05%
SMA200
-6.02%
Trades
Shs Outstand
44.83M
Shs Float
33.41M
52W High
1.50 -46.67%
52W Low
0.50 59.65%
Volatility
14.61% 12.52%
ATR (14)
0.11
RSI (14)
38.32
Beta
1.46
Rel Volume
0.00
Avg Volume
217.91K
Volume
0
Perf Week
-0.25%
Perf Month
-25.93%
Perf Quarter
11.08%
Perf Half Y
-21.57%
Perf YTD
-32.20%
Perf Year
-32.77%
Perf 3Y
-82.68%
Perf 5Y
-93.57%
Perf 10Y
-
Prev Close
0.80
Price
0.80
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$1.90
Implied Upside
+137.5%
Analysts7incl. previous ratings
Rating Distribution6 Buy · 1 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 25, 2026Initiated
CCraig Hallum
Buy$2+150.0%
Mar 21, 2025Downgrade
PPiper Sandler
Overweight → Neutral$5 → $2+150.0%
May 31, 2022Initiated
LLake Street
Buy$17+2,025.0%
Dec 03, 2019Initiated
PPiper Jaffray
Overweight
Dec 03, 2019Initiated
JJMP Securities
Mkt Outperform
Dec 03, 2019Initiated
JEF logoJJefferies
Buy
Dec 03, 2019Initiated
CCanaccord Genuity
Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Capper Joseph HDirectorSep 16 '26Buy1.1750,00058,265154,827Sep 18 04:30 PM
Capper Joseph HDirectorSep 17 '26Buy1.2225,00030,530179,827Sep 18 04:30 PM
Capper Joseph HDirectorSep 15 '26Buy1.0650,00052,940104,827Sep 16 06:46 PM
Capper Joseph HDirectorSep 14 '26Buy1.0225,00025,50254,827Sep 16 06:46 PM
Getz Heather CChief Executive OfficerAug 17 '26Buy0.6612,5008,311532,500Aug 19 04:10 PM
Getz Heather CChief Executive OfficerAug 14 '26Buy0.7015,00010,467520,000Aug 17 04:32 PM
EW HEALTHCARE PARTNERS FUND 2,10% OwnerNov 17 '25Buy1.113,604,0004,000,4407,714,709Nov 17 04:26 PM
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company was founded by Antony Koblish and Maarten Persenaire on April 17, 2012 and is headquartered in Malvern, PA.
PresidentMr. Jeffrey Blizard
M.B.A.Ms. Heather C. Getz CPA
VPMs. Megan Smeykal
Chief Technology OfficerMr. Paul Talmo
General Counsel & Corporate SecretaryMr. D. Taylor Ocasio